Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of NBI-1117568 in adults with schizophrenia
2025-521216-19-00Phase 3Authorised
- Sponsor
- Neurocrine Biosciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of direclidine in schizophrenia, sponsored by Neurocrine Biosciences. Primary endpoint: Occurrence of adverse events during the open-label treatment period. Planned start Dec 2025; status: authorised.
02
Drugs
direclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2025-521216-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521216-19-00.